Comparison of Pharmacokinetic Profiles of Beraprost Sustained Release in Japanese, Chinese, and Korean Healthy Adult Males

Background and Objectives Beraprost sodium (BPS), an orally administrable prostaglandin I 2 derivative, is used for the treatment of chronic arterial occlusion and pulmonary arterial hypertension and has potential efficacy in nephropathy. Beraprost sustained release (beraprost SR) is an oral sustained-release formulation of BPS. To confirm the dose rationale reported in a multi-regional study of nephropathy patients in Asia, this open-label study evaluated ethnic differences in the pharmacokinetic profiles of BPS and its active diastereomer (BPS-314 d ) after beraprost SR administration among healthy Japanese, Chinese, and Korean adult males. Methods Twelve healthy subjects in each ethnic group were enrolled. Subjects received a single oral dose of 120 μg beraprost SR under fasting conditions. Results The geometric mean ratio (90% confidence interval) of the maximum plasma concentration ( C max ) and area under the plasma concentration–time curve from time 0 to time of the last quantifiable concentration (AUC last ) of BPS was 1.12 (0.85–1.48) and 1.40 (1.05–1.86) in Chinese, and 1.18 (0.90–1.55) and 1.18 (0.89–1.58) in Korean compared to Japanese subjects. These differences were not clinically relevant. Similarly, differences in the C max and AUC last of BPS-314 d were also small among the ethnic groups. Urinary excretion of BPS and BPS-314 d was limited in all ethnic groups. Together, these findings indicate that the pharmacokinetics of beraprost SR are not affected by ethnic background. Conclusions There were no clinically meaningful ethnic differences in the pharmacokinetics of BPS and BPS-314 d following beraprost SR administration among Japanese, Chinese and Korean populations.